Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software

被引:14
作者
Capalbo, C
Ricevuto, E
Vestri, A
Sidoni, T
Buffone, A
Cortesi, E
Marchetti, P
Scambia, G
Tomao, S
Rinaldi, C
Zani, M
Ferraro, S
Frati, L
Screpanti, I
Gulino, A
Giannini, G
机构
[1] Univ Roma La Sapienza, Dept Expt Med & Pathol, Policlin Umberto I, I-00161 Rome, Italy
[2] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy
[3] IRCCS, IDI, Rome, Italy
[4] Catholic Univ, Dept Oncol, Campobasso, Italy
[5] Regina Elena Inst Canc Res, Dept Med Oncol, Rome, Italy
[6] Neuromed Inst, Pozzilli, Italy
关键词
BRCA1; BRCA2; breast/ovarian cancer; predictive models; Brcapro; IC software;
D O I
10.1038/sj.ejhg.5201511
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inherited mutations of the BRCA1/2 genes confer a significantly increased risk for breast and/or ovarian cancer development. Several models were elaborated to help genetic counsellors in selecting individuals with high probability of being mutation carriers. The IC software, a country-customized version of the Brcapro model, was recently shown to be particularly accurate in the prediction of carrier probability status in the Italian population. Here, we used our independent series of 70 breast/ovarian cancer families to analyze the performances of the IC software and compare it to widely used models, such as Brcapro and the Myriad mutation prevalence tables. Analysis of the areas under the receiver operator characteristics (ROC) curves indicated that overall the models performed well. However, the IC software and Myriad tables were more efficient in predicting mutated cases, showing a higher sensitivity (94 and 88%, respectively) and negative predictive value (NPV, 94 and 92%, respectively) compared to Brcapro (sensitivity 71 and NPV 83%). IC software also appeared particularly accurate in the identification of families belonging the low mutation risk group (< 10%). Finally, most Brcapro failures occurred in the hereditary breast cancer (HBC) family subset, and in 75% of the cases, the IC software corrected them. Our data suggest that the country-customized implementation operated on the Brcapro software generated a more accurate tool for the prediction of BRCA1/2 gene mutation. Whether the IC or other country-customized models might improve BRCA1/2 mutation prediction also in non-Italian families needs to be further explored.
引用
收藏
页码:49 / 54
页数:6
相关论文
共 25 条
[1]  
[Anonymous], J CLIN ONCOL
[2]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[3]   The BOADICEA model of genetic susceptibility to breast and ovarian cancer [J].
Antoniou, AC ;
Pharoah, PPD ;
Smith, P ;
Easton, DF .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1580-1590
[4]   BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes [J].
Berry, DA ;
Iversen, ES ;
Gudbjartsson, DF ;
Hiller, EH ;
Garber, JE ;
Peshkin, BN ;
Lerman, C ;
Watson, P ;
Lynch, HT ;
Hilsenbeck, SG ;
Rubinstein, WS ;
Hughes, KS ;
Parmigiani, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2701-2712
[5]   American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility [J].
Bruinooge, SS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2397-2406
[6]   BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer [J].
Couch, FJ ;
DeShano, ML ;
Blackwood, MA ;
Calzone, K ;
Stopfer, J ;
Campeau, L ;
Ganguly, A ;
Rebbeck, T ;
Weber, BL ;
Jablon, L ;
Cobleigh, MA ;
Hoskins, K ;
Garber, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (20) :1409-1415
[7]   Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families:: Implications for genetic testing [J].
de la Hoya, M ;
Osorio, A ;
Godino, J ;
Sulleiro, S ;
Tosar, A ;
Perez-Segura, P ;
Fernandez, C ;
Rodríguez, R ;
Díaz-Rubio, E ;
Benítez, J ;
Devilee, P ;
Caldés, T .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (04) :466-471
[8]   COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH [J].
DELONG, ER ;
DELONG, DM ;
CLARKEPEARSON, DI .
BIOMETRICS, 1988, 44 (03) :837-845
[9]  
EASTON DF, 1995, AM J HUM GENET, V56, P265
[10]   Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO [J].
Euhus, DM ;
Smith, KC ;
Robinson, L ;
Stucky, A ;
Olopade, OI ;
Cummings, S ;
Garber, JE ;
Chittenden, A ;
Mills, GB ;
Rieger, P ;
Esserman, L ;
Crawford, B ;
Hughes, KS ;
Roche, CA ;
Ganz, PA ;
Seldon, J ;
Fabian, CJ ;
Klemp, J ;
Tomlinson, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (11) :844-851